Wednesday, May 18, 2022

Latest:

Healthy Habits: Dr. Felicia Skelton-Dudley starts her day with quiet reflection and practices yoga
Dr. Susan Rosenberg elected to AAAS Board of Directors
Spring cleaning safety tips
Social burnout post-pandemic
Alone at the hands of healthcare: hospital visitor policies during the COVID-19 pandemic

Baylor College of Medicine Blog Network

Blog Network
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

kidney cancer

From The Labs

PBRM1’s new function supports a novel cancer-promoting mechanism

October 14, 2021October 14, 2021Cancer, chromatin remodeler, cytoskleleton remodeler, genomic instability, kidney cancer, PBRM1, Research, SETD2, tubulin methylation

New findings suggest that cancer-associated defects in chromatin remodeler genes can drive cancer by disrupting cytoskeletal activities.

From The Labs

Playing with the physics of gels leads to a better kidney cancer treatment

May 14, 2020May 21, 2020cancer treatment, FDA approved, Jelmyto, kidney cancer, mitomycin, Research, UGN-101, Urothelial cancer

Effectively treating upper tract urothelial cancer – a cancer of the lining of the kidney or the ureter, the long, thin tube that connects that

From The Labs

Chromosome remodeler SETD2 also remodels the cytoskeleton in kidney cancer cells

August 30, 2016March 9, 2018Cancer, chromosome remodeler, cytoskeleton remodeler, epigenetics, kidney cancer, methyl tags, Research, SETD2

Kidney cancer begins when certain genes mutate and, as a result, alter how key molecules work. One of these key molecules is SETD2, which is

From the Labs: A closer look at tertiary lymphoid structures. Image courtesy of M. Zelazowski/ P. Castro/Baylor’s Human Tissue Acquisition & Pathology (HTAP) Core.